Immune checkpoint inhibitors have transformed the treatment of many cancers by unleashing T cells against tumor cells, but that same unleashing can occasionally turn against the heart. Immune checkpoint inhibitor-associated myocarditis, or ICI-myocarditis, is among the rarest yet most feared immune-related adverse events of modern oncology, with mortality rates that remain unacceptably high and diagnostic tools that are largely indirect. Now, a team of researchers at Zhongshan Hospital, Fudan University, in Shanghai has produced one of the most detailed molecular portraits of the condition to date, combining single-cell RNA sequencing, flow cytometry, Olink proteomics, and multiplex cytokine profiling to map the immune landscape of patients who develop this devastating complication. The study, published in Nature Communications, identifies a specific population of interferon-stimulated CD8-positive T cells as a central driver of cardiac injury and points toward both a diagnostic blood test and a therapeutic strategy.

The challenge that motivated the work is well known to cardio-oncologists. When a patient receiving checkpoint inhibitors develops chest pain, arrhythmias, or rising cardiac troponin levels, clinicians must distinguish true ICI-myocarditis from other causes of cardiac stress in a cancer population. Current diagnosis relies heavily on biomarkers, electrocardiography, cardiac magnetic resonance imaging, and, in severe cases, endomyocardial biopsy, which is invasive and rarely performed early. Without a clear molecular understanding of what the immune system is actually doing during the attack on heart muscle, the field has lacked both precise diagnostics and rational targeted therapies. The Shanghai group set out to close that gap by examining immune cells directly, at single-cell resolution, in patients before and after the onset of disease.

Using single-cell RNA sequencing of peripheral blood mononuclear cells, the researchers profiled the circulating immune compartment of patients with ICI-myocarditis and compared it with that of cancer patients receiving checkpoint inhibitors who remained free of cardiac toxicity. The analysis revealed a striking expansion of a subset of CD8-positive T cells expressing ISG15, a protein induced by type I interferon signaling. These ISG15-positive CD8 T cells carried a strongly proinflammatory transcriptional program, suggesting they were not passive bystanders but active participants in the autoimmune assault on the myocardium. The finding was consistent across patients and was corroborated by independent flow cytometry measurements of the same cell populations.

Crucially, the ISG15-positive T cells did not appear to act alone. The single-cell data showed that their abundance at baseline correlated with proinflammatory features in monocytes, the innate immune cells that can amplify tissue damage through cytokine release and antigen presentation. Computational analysis of ligand-receptor interactions across cell types suggested that the communication between these two compartments may be mediated, at least in part, by the CCL2-CCR2 chemokine axis, a well-characterized signaling pathway that recruits monocytes expressing the CCR2 receptor toward sites of inflammation. In other words, the T cells appeared to summon and activate the monocytes, creating a self-reinforcing inflammatory loop in the heart.

To test whether these circulating cells were genuinely cardiotoxic rather than merely correlated with disease, the team performed in vitro experiments. They isolated the ISG15-positive CD8 T cells from patient blood and co-cultured them with cardiomyocytes, observing that these cells showed a high potential to induce apoptosis, or programmed cell death, in the heart muscle cells. This functional evidence supports the pathogenic role that the transcriptional data had implied: the very cells enriched in patients who develop myocarditis carry the molecular machinery to kill cardiomyocytes. It is a direct demonstration, at the cellular level, of how checkpoint inhibitor therapy can tip the immune system toward self-destruction of cardiac tissue.

The translational payoff of the study comes in two forms. The first is diagnostic. Based on the inflammatory signature identified in the multi-omics data, the researchers developed a custom panel of eight proteins measurable in blood, selected from the proteomic and cytokine profiles that distinguished ICI-myocarditis patients from other checkpoint inhibitor-treated controls. The panel showed promising performance in separating true myocarditis from patients on the same drugs who did not develop cardiac toxicity. If validated in larger, prospective cohorts, such a panel could allow oncologists and cardiologists to identify or rule out ICI-myocarditis earlier and with greater confidence than current biomarkers alone, potentially preventing the delays that contribute to the condition’s high fatality rate.

The second payoff is therapeutic. The integrated analysis pointed to JAK-STAT signaling, a central intracellular pathway downstream of many inflammatory cytokine receptors, as a shared driver of the inflammatory programs in both the ISG15-positive CD8 T cells and the activated monocytes. In mouse models of ICI-induced cardiac injury, pharmacological inhibition of the JAK-STAT pathway ameliorated cardiac dysfunction and reduced inflammatory infiltration into the heart. Remarkably, the intervention did not simply blunt the autoimmune attack; it also enhanced the response to anti-PD-1 therapy in the same models. That dual effect is significant because the ideal treatment for ICI-myocarditis would suppress the cardiac toxicity without sacrificing the anti-tumor benefit that motivated checkpoint blockade in the first place.

The chemokine axis offered a parallel therapeutic target. When the researchers blocked the CCL2-CCR2 axis in vivo, the intervention attenuated ICI-induced cardiac injury in the animal models, consistent with the idea that disrupting the recruitment of CCR2-expressing monocytes can break the inflammatory loop that damages the myocardium. Together, the JAK-STAT and CCL2-CCR2 findings suggest that ICI-myocarditis is not an undifferentiated inflammatory storm but a structured pathological circuit with defined nodes that can be pharmacologically intercepted. Each node represents a potential drug target, and several JAK inhibitors and CCR2 antagonists already exist in the clinical pharmacology arsenal for other inflammatory diseases, which could accelerate the path to clinical testing.

The study also carries implications for risk prediction before therapy begins. The observation that high levels of baseline ISG15-positive CD8 T cells are linked to the development of myocarditis raises the possibility of screening patients before they start checkpoint inhibitors, identifying those whose immune systems are already primed for interferon-driven, cytotoxic anti-cardiac responses. Such pre-treatment stratification remains speculative until prospective studies confirm the predictive value of the signature, but it fits a broader trend in immuno-oncology toward tailoring therapy to a patient’s baseline immune state rather than reacting to toxicity after it appears.

Cautions remain. The human findings rest on peripheral blood measurements, which serve as a window into the immune response but do not fully capture the inflammatory milieu inside the heart muscle itself, where tissue-resident immune populations may behave differently. The mouse models, while supportive, recapitulate only parts of the human disease. And the eight-protein diagnostic panel, however promising, will need rigorous external validation across diverse cancer types, treatment regimens, and ethnic populations before it can enter routine clinical use. Nevertheless, by integrating single-cell transcriptomics, proteomics, cytokine profiling, and functional experiments into a single coherent picture, the Zhongshan Hospital team has converted a poorly understood, frequently fatal complication into a molecularly defined disease with identifiable cellular culprits, a candidate blood-based diagnostic, and two mechanistically grounded therapeutic strategies. For the growing population of patients whose cancers are treated with checkpoint inhibitors, that transformation is a meaningful step toward making immunotherapy’s most dangerous side effect predictable, detectable, and treatable.

Subject of Research: Immune mechanisms, diagnosis, and treatment of immune checkpoint inhibitor-induced myocarditis

Article Title: Integrated multi-omics identifies distinct immune signatures with diagnostic and therapeutic implications in immune checkpoint inhibitor-induced myocarditis

Article References: Integrated multi-omics identifies distinct immune signatures with diagnostic and therapeutic implications in immune checkpoint inhibitor-induced myocarditis. (n.d.). https://doi.org/10.1038/s41467-026-77262-0

Image Credits: AI Generated

DOI: 10.1038/s41467-026-77262-0

Keywords: immune checkpoint inhibitors, myocarditis, CD8 T cells, ISG15, monocytes, CCL2-CCR2 axis, JAK-STAT pathway, single-cell RNA sequencing, proteomics, cardiotoxicity, cancer immunotherapy, biomarkers